Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 148 | 2023 | 15708 | 2.930 |
Why?
|
Mastectomy, Segmental | 37 | 2021 | 1026 | 1.900 |
Why?
|
Carcinoma, Ductal, Breast | 22 | 2018 | 1219 | 1.420 |
Why?
|
Neoplasm Recurrence, Local | 64 | 2021 | 10070 | 1.200 |
Why?
|
Mastectomy | 41 | 2020 | 1538 | 1.110 |
Why?
|
Brachial Plexus | 1 | 2022 | 45 | 0.850 |
Why?
|
Carcinoma, Lobular | 11 | 2018 | 613 | 0.830 |
Why?
|
Radiotherapy Dosage | 31 | 2018 | 3846 | 0.780 |
Why?
|
Patient Positioning | 2 | 2015 | 195 | 0.760 |
Why?
|
Radiotherapy, Conformal | 6 | 2019 | 902 | 0.740 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 16 | 2015 | 2373 | 0.680 |
Why?
|
Skin | 4 | 2014 | 1261 | 0.680 |
Why?
|
Lymphatic Metastasis | 40 | 2019 | 4847 | 0.650 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 8 | 2021 | 676 | 0.640 |
Why?
|
Proton Therapy | 6 | 2020 | 1577 | 0.610 |
Why?
|
Breast | 10 | 2021 | 1350 | 0.600 |
Why?
|
Radiotherapy, Adjuvant | 34 | 2021 | 2233 | 0.590 |
Why?
|
Photons | 4 | 2014 | 507 | 0.530 |
Why?
|
Chemotherapy, Adjuvant | 42 | 2019 | 3892 | 0.510 |
Why?
|
Radiation Injuries | 8 | 2018 | 1412 | 0.490 |
Why?
|
Brachytherapy | 5 | 2018 | 978 | 0.470 |
Why?
|
Female | 147 | 2023 | 142295 | 0.460 |
Why?
|
Lymph Node Excision | 19 | 2023 | 1960 | 0.420 |
Why?
|
Breast Cancer Lymphedema | 2 | 2023 | 38 | 0.420 |
Why?
|
Combined Modality Therapy | 47 | 2019 | 8882 | 0.400 |
Why?
|
Mastectomy, Modified Radical | 6 | 2010 | 70 | 0.400 |
Why?
|
Lymphedema | 4 | 2023 | 239 | 0.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2014 | 15881 | 0.390 |
Why?
|
Neoplasm Staging | 35 | 2019 | 13673 | 0.390 |
Why?
|
Neoadjuvant Therapy | 23 | 2015 | 4980 | 0.380 |
Why?
|
Lymphatic Irradiation | 6 | 2009 | 133 | 0.380 |
Why?
|
Humans | 160 | 2023 | 262300 | 0.340 |
Why?
|
Middle Aged | 103 | 2021 | 86512 | 0.340 |
Why?
|
Lymph Nodes | 15 | 2015 | 2969 | 0.330 |
Why?
|
Doxorubicin | 22 | 2011 | 3005 | 0.330 |
Why?
|
Mammaplasty | 8 | 2017 | 780 | 0.320 |
Why?
|
Adult | 97 | 2021 | 78140 | 0.320 |
Why?
|
Mastectomy, Radical | 4 | 2005 | 39 | 0.320 |
Why?
|
Mammography | 9 | 2015 | 1011 | 0.320 |
Why?
|
Monte Carlo Method | 2 | 2010 | 672 | 0.300 |
Why?
|
Retrospective Studies | 65 | 2021 | 38030 | 0.300 |
Why?
|
Aged | 75 | 2021 | 70372 | 0.290 |
Why?
|
Radiotherapy | 11 | 2017 | 1827 | 0.290 |
Why?
|
Axilla | 14 | 2015 | 903 | 0.280 |
Why?
|
Iridium Radioisotopes | 1 | 2006 | 56 | 0.280 |
Why?
|
Electrons | 3 | 2010 | 171 | 0.280 |
Why?
|
Phantoms, Imaging | 4 | 2006 | 1275 | 0.270 |
Why?
|
Follow-Up Studies | 28 | 2020 | 14910 | 0.270 |
Why?
|
Disease-Free Survival | 31 | 2017 | 10025 | 0.250 |
Why?
|
Ultrasonography, Mammary | 4 | 2015 | 381 | 0.240 |
Why?
|
Carcinoma in Situ | 4 | 2005 | 485 | 0.220 |
Why?
|
Radiation Oncology | 4 | 2020 | 529 | 0.210 |
Why?
|
Treatment Outcome | 43 | 2021 | 33021 | 0.200 |
Why?
|
Receptors, Progesterone | 3 | 2012 | 1388 | 0.190 |
Why?
|
Lymphatic Vessels | 1 | 2022 | 143 | 0.190 |
Why?
|
Computer Simulation | 1 | 2006 | 1531 | 0.190 |
Why?
|
Receptors, Estrogen | 5 | 2012 | 2084 | 0.190 |
Why?
|
Radiotherapy, High-Energy | 3 | 1998 | 295 | 0.190 |
Why?
|
Paclitaxel | 6 | 2011 | 1998 | 0.180 |
Why?
|
Duodenal Ulcer | 1 | 2000 | 113 | 0.180 |
Why?
|
Radiography | 6 | 2010 | 1914 | 0.180 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 1047 | 0.170 |
Why?
|
Prospective Studies | 20 | 2023 | 12927 | 0.170 |
Why?
|
Radiodermatitis | 2 | 2011 | 76 | 0.170 |
Why?
|
Cosmetics | 1 | 2018 | 17 | 0.160 |
Why?
|
Clavicle | 5 | 2010 | 65 | 0.160 |
Why?
|
Survival Analysis | 25 | 2009 | 9197 | 0.160 |
Why?
|
Movement | 3 | 2011 | 557 | 0.160 |
Why?
|
Sternum | 1 | 2019 | 100 | 0.160 |
Why?
|
Tissue Expansion | 2 | 2017 | 71 | 0.160 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2018 | 2107 | 0.160 |
Why?
|
Patient Reported Outcome Measures | 2 | 2021 | 803 | 0.160 |
Why?
|
Survival Rate | 15 | 2017 | 12240 | 0.150 |
Why?
|
Surgical Flaps | 6 | 2007 | 927 | 0.150 |
Why?
|
Multivariate Analysis | 11 | 2015 | 4323 | 0.150 |
Why?
|
Margins of Excision | 1 | 2019 | 285 | 0.150 |
Why?
|
Radiation Dosage | 5 | 2006 | 1016 | 0.140 |
Why?
|
Sentinel Lymph Node Biopsy | 5 | 2014 | 1417 | 0.140 |
Why?
|
Prognosis | 20 | 2018 | 21745 | 0.140 |
Why?
|
Aged, 80 and over | 25 | 2021 | 30002 | 0.140 |
Why?
|
Treatment Failure | 6 | 2011 | 1392 | 0.140 |
Why?
|
Capecitabine | 1 | 2017 | 388 | 0.140 |
Why?
|
Reimbursement Mechanisms | 1 | 2016 | 78 | 0.130 |
Why?
|
Analysis of Variance | 11 | 2010 | 2310 | 0.130 |
Why?
|
Receptor, ErbB-2 | 3 | 2012 | 2519 | 0.130 |
Why?
|
Supine Position | 1 | 2015 | 46 | 0.130 |
Why?
|
Time Factors | 16 | 2021 | 12983 | 0.130 |
Why?
|
Risk Assessment | 11 | 2021 | 6896 | 0.130 |
Why?
|
Fluorouracil | 11 | 2011 | 1946 | 0.130 |
Why?
|
Fetus | 1 | 1998 | 593 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 3 | 2010 | 724 | 0.130 |
Why?
|
Mediastinal Neoplasms | 1 | 2019 | 422 | 0.130 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 802 | 0.120 |
Why?
|
Body Mass Index | 4 | 2010 | 2213 | 0.120 |
Why?
|
Communication | 1 | 2020 | 880 | 0.120 |
Why?
|
Cyclophosphamide | 12 | 2011 | 3084 | 0.110 |
Why?
|
Medicare | 2 | 2016 | 896 | 0.110 |
Why?
|
Epothilones | 1 | 2013 | 54 | 0.110 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2009 | 224 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2015 | 289 | 0.110 |
Why?
|
Exercise | 1 | 2000 | 1186 | 0.110 |
Why?
|
Coronary Vessels | 2 | 2011 | 667 | 0.100 |
Why?
|
Emollients | 1 | 2011 | 12 | 0.100 |
Why?
|
Petrolatum | 1 | 2011 | 11 | 0.100 |
Why?
|
Prostheses and Implants | 2 | 2007 | 297 | 0.100 |
Why?
|
Age Factors | 4 | 2011 | 5386 | 0.100 |
Why?
|
Scattering, Radiation | 2 | 2010 | 316 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2000 | 552 | 0.100 |
Why?
|
Risk Factors | 17 | 2021 | 17611 | 0.100 |
Why?
|
Brain Neoplasms | 3 | 2020 | 4838 | 0.100 |
Why?
|
Melanoma | 5 | 2002 | 5320 | 0.100 |
Why?
|
Radiation-Protective Agents | 1 | 2011 | 128 | 0.100 |
Why?
|
Inhalation | 1 | 2011 | 42 | 0.100 |
Why?
|
Algorithms | 3 | 2014 | 3891 | 0.100 |
Why?
|
Canada | 3 | 2021 | 431 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 1301 | 0.090 |
Why?
|
Drug Administration Schedule | 8 | 2017 | 3482 | 0.090 |
Why?
|
Mammary Arteries | 2 | 2005 | 64 | 0.090 |
Why?
|
Hyaluronic Acid | 1 | 2011 | 165 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6223 | 0.090 |
Why?
|
Neoplasm Invasiveness | 6 | 2017 | 3985 | 0.090 |
Why?
|
Patient Selection | 4 | 2008 | 2061 | 0.090 |
Why?
|
Myocardial Contraction | 1 | 2011 | 294 | 0.090 |
Why?
|
Odds Ratio | 5 | 2015 | 2326 | 0.090 |
Why?
|
Triple Negative Breast Neoplasms | 2 | 2017 | 1215 | 0.080 |
Why?
|
Tamoxifen | 5 | 2006 | 875 | 0.080 |
Why?
|
BRCA1 Protein | 2 | 2021 | 495 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2011 | 750 | 0.080 |
Why?
|
Cohort Studies | 9 | 2021 | 9290 | 0.080 |
Why?
|
Coronary Angiography | 1 | 2011 | 602 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2005 | 839 | 0.080 |
Why?
|
Respiration | 1 | 2010 | 447 | 0.080 |
Why?
|
Skin Neoplasms | 4 | 2009 | 4656 | 0.080 |
Why?
|
Tumor Burden | 2 | 2011 | 1991 | 0.080 |
Why?
|
Models, Statistical | 1 | 2014 | 1177 | 0.080 |
Why?
|
Nomograms | 1 | 2010 | 314 | 0.080 |
Why?
|
Radiometry | 1 | 2013 | 983 | 0.070 |
Why?
|
Regression Analysis | 5 | 2014 | 1550 | 0.070 |
Why?
|
Heart | 2 | 2011 | 1226 | 0.070 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 5010 | 0.070 |
Why?
|
Neoplasm Proteins | 3 | 2010 | 3235 | 0.070 |
Why?
|
Chi-Square Distribution | 3 | 2015 | 1329 | 0.070 |
Why?
|
Carotid Arteries | 1 | 2008 | 240 | 0.070 |
Why?
|
Postoperative Period | 3 | 2004 | 667 | 0.070 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2002 | 856 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
Carotid Stenosis | 1 | 2008 | 176 | 0.070 |
Why?
|
Taxoids | 1 | 2010 | 970 | 0.070 |
Why?
|
Hypothyroidism | 1 | 2008 | 205 | 0.070 |
Why?
|
Salvage Therapy | 2 | 2005 | 2060 | 0.070 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 362 | 0.070 |
Why?
|
United States | 8 | 2021 | 15564 | 0.070 |
Why?
|
Remission Induction | 2 | 2009 | 3584 | 0.060 |
Why?
|
Thoracic Arteries | 1 | 2005 | 10 | 0.060 |
Why?
|
Texas | 7 | 2020 | 6309 | 0.060 |
Why?
|
Early Termination of Clinical Trials | 2 | 2017 | 85 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2015 | 6042 | 0.060 |
Why?
|
Catheterization | 2 | 2004 | 410 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 6 | 2014 | 7580 | 0.060 |
Why?
|
Seroma | 2 | 2018 | 80 | 0.060 |
Why?
|
Adenocarcinoma | 4 | 2008 | 7793 | 0.060 |
Why?
|
Ataxia Telangiectasia | 1 | 2004 | 62 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2021 | 1947 | 0.060 |
Why?
|
Positron-Emission Tomography | 2 | 2009 | 2182 | 0.060 |
Why?
|
Carcinoma, Ductal | 1 | 2004 | 145 | 0.060 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2004 | 127 | 0.060 |
Why?
|
Neoplasms, Second Primary | 2 | 2003 | 1350 | 0.050 |
Why?
|
Antineoplastic Agents | 7 | 2012 | 14302 | 0.050 |
Why?
|
Radiology | 1 | 2008 | 434 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2004 | 642 | 0.050 |
Why?
|
Ultrasonography, Interventional | 1 | 2005 | 433 | 0.050 |
Why?
|
Logistic Models | 4 | 2015 | 3450 | 0.050 |
Why?
|
Medical Records | 2 | 2020 | 414 | 0.050 |
Why?
|
Quality of Life | 3 | 2023 | 4579 | 0.050 |
Why?
|
Societies, Medical | 1 | 2008 | 1342 | 0.050 |
Why?
|
Professional Staff Committees | 1 | 2001 | 30 | 0.050 |
Why?
|
Clinical Trials as Topic | 6 | 2010 | 3757 | 0.050 |
Why?
|
Gene Frequency | 1 | 2004 | 1165 | 0.050 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2012 | 3264 | 0.050 |
Why?
|
Actuarial Analysis | 2 | 2002 | 159 | 0.050 |
Why?
|
Edema | 2 | 2018 | 267 | 0.050 |
Why?
|
Thoracic Neoplasms | 1 | 2003 | 337 | 0.050 |
Why?
|
Stainless Steel | 1 | 1999 | 27 | 0.050 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 1267 | 0.050 |
Why?
|
Hospitals, University | 1 | 2020 | 211 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2006 | 6610 | 0.040 |
Why?
|
Body Image | 1 | 2021 | 141 | 0.040 |
Why?
|
Observer Variation | 2 | 2014 | 672 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 505 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2023 | 298 | 0.040 |
Why?
|
Confidence Intervals | 3 | 2006 | 756 | 0.040 |
Why?
|
Germ Cells | 1 | 2021 | 338 | 0.040 |
Why?
|
Adolescent | 9 | 2019 | 31274 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 309 | 0.040 |
Why?
|
Lung | 1 | 2010 | 3168 | 0.040 |
Why?
|
Neoplasm, Residual | 4 | 2011 | 1668 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2001 | 316 | 0.040 |
Why?
|
Pneumonia | 1 | 2004 | 754 | 0.040 |
Why?
|
Anus Neoplasms | 1 | 2002 | 412 | 0.040 |
Why?
|
Risk | 2 | 2014 | 1974 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2021 | 291 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 5539 | 0.040 |
Why?
|
Patient Satisfaction | 2 | 2020 | 928 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2017 | 62 | 0.040 |
Why?
|
Radiation Protection | 1 | 1998 | 204 | 0.040 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
Young Adult | 5 | 2019 | 21505 | 0.040 |
Why?
|
Family | 1 | 2000 | 737 | 0.040 |
Why?
|
Clinical Coding | 1 | 2016 | 28 | 0.030 |
Why?
|
Fat Necrosis | 2 | 2007 | 64 | 0.030 |
Why?
|
Postoperative Care | 2 | 2014 | 740 | 0.030 |
Why?
|
Nipples | 2 | 2007 | 132 | 0.030 |
Why?
|
Patient Care Planning | 1 | 1998 | 297 | 0.030 |
Why?
|
SEER Program | 2 | 2010 | 1000 | 0.030 |
Why?
|
Postoperative Complications | 4 | 2007 | 5567 | 0.030 |
Why?
|
Biopsy, Needle | 2 | 2015 | 1364 | 0.030 |
Why?
|
Fibrosis | 1 | 2018 | 768 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 306 | 0.030 |
Why?
|
Mastectomy, Simple | 2 | 1993 | 58 | 0.030 |
Why?
|
Sex Factors | 1 | 2000 | 2157 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 1999 | 1064 | 0.030 |
Why?
|
Preoperative Care | 2 | 2017 | 1529 | 0.030 |
Why?
|
Rectal Neoplasms | 1 | 2002 | 1203 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 4902 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2003 | 1396 | 0.030 |
Why?
|
Spinal Cord Neoplasms | 1 | 1995 | 145 | 0.030 |
Why?
|
Physical Examination | 1 | 2015 | 298 | 0.030 |
Why?
|
Prone Position | 1 | 2013 | 56 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 7730 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2009 | 2631 | 0.030 |
Why?
|
Probability | 2 | 2004 | 868 | 0.030 |
Why?
|
Esthetics | 2 | 2007 | 189 | 0.030 |
Why?
|
Breast Implants | 1 | 2017 | 391 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2004 | 5185 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2015 | 673 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 949 | 0.030 |
Why?
|
Medical Oncology | 1 | 2020 | 1425 | 0.030 |
Why?
|
Etoposide | 2 | 2006 | 873 | 0.030 |
Why?
|
Pregnancy | 2 | 2009 | 7552 | 0.030 |
Why?
|
Administration, Topical | 1 | 2011 | 259 | 0.020 |
Why?
|
Carcinoma | 1 | 2003 | 2583 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 2 | 2008 | 927 | 0.020 |
Why?
|
Palliative Care | 2 | 2019 | 2032 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 4949 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 414 | 0.020 |
Why?
|
Ultrasonography, Doppler, Color | 2 | 2005 | 100 | 0.020 |
Why?
|
Helicobacter pylori | 1 | 2000 | 1292 | 0.020 |
Why?
|
Helicobacter Infections | 1 | 2000 | 1213 | 0.020 |
Why?
|
British Columbia | 1 | 2010 | 24 | 0.020 |
Why?
|
Organ Size | 1 | 2011 | 690 | 0.020 |
Why?
|
Incidence | 3 | 2005 | 5712 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2015 | 4348 | 0.020 |
Why?
|
Pain | 1 | 2018 | 1674 | 0.020 |
Why?
|
Consensus | 1 | 2014 | 1004 | 0.020 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 2 | 2004 | 427 | 0.020 |
Why?
|
Neoplasm Metastasis | 3 | 2009 | 5123 | 0.020 |
Why?
|
Forecasting | 2 | 2004 | 695 | 0.020 |
Why?
|
Trastuzumab | 1 | 2012 | 697 | 0.020 |
Why?
|
Disease Management | 1 | 2015 | 1061 | 0.020 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2010 | 342 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2000 | 1833 | 0.020 |
Why?
|
Premenopause | 1 | 2009 | 132 | 0.020 |
Why?
|
Transplantation, Autologous | 2 | 2006 | 1925 | 0.020 |
Why?
|
Registries | 2 | 2008 | 2188 | 0.020 |
Why?
|
Neoplasm Grading | 1 | 2013 | 1750 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2005 | 5777 | 0.020 |
Why?
|
Efficiency | 1 | 2008 | 99 | 0.020 |
Why?
|
Ultrasonics | 1 | 2008 | 69 | 0.020 |
Why?
|
Prednisone | 2 | 2001 | 983 | 0.020 |
Why?
|
Postmenopause | 1 | 2009 | 377 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2008 | 276 | 0.020 |
Why?
|
Population Surveillance | 1 | 2010 | 628 | 0.020 |
Why?
|
ROC Curve | 1 | 2010 | 1180 | 0.020 |
Why?
|
Thermoluminescent Dosimetry | 1 | 2006 | 77 | 0.020 |
Why?
|
Methotrexate | 1 | 2010 | 1013 | 0.020 |
Why?
|
Vincristine | 2 | 2001 | 1511 | 0.020 |
Why?
|
Neutropenia | 2 | 2002 | 968 | 0.020 |
Why?
|
Male | 6 | 2019 | 123333 | 0.020 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2009 | 389 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1995 | 1435 | 0.020 |
Why?
|
Ultrasonography | 1 | 2012 | 1870 | 0.020 |
Why?
|
Cisplatin | 2 | 2006 | 2432 | 0.020 |
Why?
|
Rectus Abdominis | 1 | 2006 | 100 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 4979 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2006 | 6105 | 0.020 |
Why?
|
Calibration | 1 | 2005 | 337 | 0.020 |
Why?
|
Overweight | 1 | 2007 | 486 | 0.010 |
Why?
|
Chemoradiotherapy | 1 | 2013 | 1947 | 0.010 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2004 | 88 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2000 | 5435 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 2 | 2004 | 1825 | 0.010 |
Why?
|
Age Distribution | 1 | 2005 | 704 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 2005 | 231 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2015 | 5713 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2005 | 372 | 0.010 |
Why?
|
Cicatrix | 1 | 2005 | 203 | 0.010 |
Why?
|
Cell Cycle Proteins | 2 | 2004 | 2053 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2004 | 261 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2004 | 727 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 1309 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2003 | 444 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 1562 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2007 | 1237 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
Arm | 1 | 2002 | 147 | 0.010 |
Why?
|
Organizational Objectives | 1 | 2001 | 65 | 0.010 |
Why?
|
Radiation Tolerance | 1 | 2004 | 629 | 0.010 |
Why?
|
Recurrence | 2 | 2002 | 4785 | 0.010 |
Why?
|
Equipment Design | 1 | 2004 | 1207 | 0.010 |
Why?
|
Arteries | 1 | 2001 | 272 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 980 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 3270 | 0.010 |
Why?
|
Melanoma, Amelanotic | 1 | 1998 | 9 | 0.010 |
Why?
|
Fever | 1 | 2002 | 498 | 0.010 |
Why?
|
DNA-Binding Proteins | 2 | 2004 | 4788 | 0.010 |
Why?
|
Vinblastine | 1 | 1998 | 453 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 4888 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2007 | 2421 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2001 | 548 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2004 | 6064 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 1998 | 310 | 0.010 |
Why?
|
BRCA2 Protein | 1 | 1999 | 359 | 0.010 |
Why?
|
Dacarbazine | 1 | 1998 | 483 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 4756 | 0.010 |
Why?
|
Genes, BRCA1 | 1 | 1999 | 387 | 0.010 |
Why?
|
Genetic Variation | 1 | 2004 | 2090 | 0.010 |
Why?
|
Smoking | 1 | 2005 | 2444 | 0.010 |
Why?
|
Interleukin-2 | 1 | 1998 | 843 | 0.010 |
Why?
|
Obesity | 1 | 2007 | 2892 | 0.010 |
Why?
|
Interferon-alpha | 1 | 1998 | 889 | 0.010 |
Why?
|
Genes, p53 | 1 | 1999 | 1093 | 0.010 |
Why?
|
Feasibility Studies | 1 | 1999 | 2304 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1999 | 1905 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1998 | 2918 | 0.010 |
Why?
|
Decision Making | 1 | 2000 | 1295 | 0.010 |
Why?
|
Biopsy | 1 | 2000 | 3452 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 1999 | 1684 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 2010 | 10348 | 0.010 |
Why?
|
Proteins | 1 | 1999 | 1954 | 0.010 |
Why?
|
Transcription Factors | 1 | 1999 | 5257 | 0.000 |
Why?
|